Circle of Willis Atherosclerosis Is a Risk Factor for Sporadic Alzheimer's Disease

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 23, Issue 11, 2003, Pages 2055-2062

  Roher, Alex E ^a   Esh, Chera ^a   Kokjohn, Tyler A ^b   Kalback, Walter ^a   Luehrs, Dean C ^a   Seward, James D ^a   Sue, Lucia I ^a   Beach, Thomas G ^b  

^a SUN HEALTH RESEARCH INSTITUTE   (United States)

^b NONE

Author keywords

Alzheimer's disease; Atherosclerosis; Brain hypoperfusion; Circle of Willis

Indexed keywords

AGED; ALZHEIMER DISEASE; ARTERY OCCLUSION; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; AUTOPSY; BRAIN CIRCULUS ARTERIOSUS; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; PRIORITY JOURNAL; RISK FACTOR; WHITE MATTER;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AUTOPSY; CARDIOVASCULAR DISEASES; CEREBROVASCULAR ACCIDENT; CIRCLE OF WILLIS; COMORBIDITY; FEMALE; HUMANS; INCIDENCE; INTRACRANIAL ARTERIOSCLEROSIS; MALE; MIDDLE CEREBRAL ARTERY; NEUROFIBRILLARY TANGLES; RISK FACTORS; SEX DISTRIBUTION;

EID: 0242628969     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000095973.42032.44     Document Type: Article

References (73)

1. Breteler MM. Vascular risk factors for Alzheimer's disease: an epidemiologic perspective. Neurobiol Aging. 2000;21:153-160.
2. Stewart R. Cardiovascular factors in Alzheimer's disease. J Neurol Neurosurg Psychiatry. 1998;65:143-147.
3. Skoog I, Kalaria RN, Breteler MM. Vascular factors and Alzheimer's disease. Alzheimer Dis Assoc Disord. 1999;13:106-114.
4. Breteler MM. Vascular involvement in cognitive decline and dementia: epidemiologic evidence from the Rotterdam study and the Rotterdam scan study. Ann N Y Acad Sci. 2000;903:457-465.
5. Breteler MM, Bots ML, Ott A, Hofman A. Risk factors for vascular disease and dementia. Homeostasis. 1998;28:167-173.
6. Meyer JS, Rauch GM, Rauch RA, Haque A, Crawford K. Cardiovascular and other risk factors for Alzheimer's disease and vascular dementia. Ann N Y Acad Sci. 2000;903:411-423.
7. Kalmijn S, Foley D, White L, Burchfiel CM, Curb JD, Petrovitch H, Ross GW, Havlik RJ, Launer LJ. Metabolic cardiovascular syndrome and risk of dementia in Japanese-American elderly men. Arterioscler Thromb Vasc Biol. 2000;20:2255-2260.
8. de la Torre JC. Alzheimer disease as a vascular disorder: nosological evidence. Stroke. 2002;33:1152-1162.
9. de la Torre JC. Alzheimer's disease: how does it start? J Alzheimer Dis. 2002;4:497-512.
10. Sparks DL, Hunsaker JC, Scheff SW, Kryscio RJ, Henson JL, Markesbery WR. Cortical senile plaques in coronary artery disease, aging and Alzheimer's disease. Neurobiol Aging. 1990;11:601-607.
11. Soneira CF, Scott TM. Severe cardiovascular disease and Alzheimer's disease: senile plaque formation in cortical areas. Clin Anat. 1996;9:118-127.
12. Aronson MK, Ooi WL, Morgenstern H, Hafner A, Masur D, Crystal H, Frishman WH, Fisher D, Katzman R. Women, myocardial infarction, and dementia in the very old. Neurology. 1990;40:1102-1106.
13. Wisniewski HM, Maslinska D. β-protein immunoreactivity in the human brain after cardiac arrest. Folia Neuropathol. 1996;34:65-71.
14. Hofman A, Ott A, Breteler MM, Bots ML, Slooter AJ, van Harskamp F, van Duijn CN, Van Broeckhoven C, Grobbee DE. Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study. Lancet. 1997;349:151-154.
15. Schmidt R, Schmidt H, Curb JD, Masaki K, White LR, Launer LJ. Early inflammation and dementia: a 25-year follow-up of the Honolulu-Asia aging study. Ann Neurol. 2002;52:168-174.
16. Swan GE, Carmelli D, Larue A. Systolic blood pressure tracking over 25 to 30 years and cognitive performance in older adults. Stroke. 1998;29:2334-2340.
17. Skoog I, Lernfelt B, Landahl S, Palmertz B, Andreasson LA, Nilsson L, Persson G, Oden A, Svanborg A. 15-year longitudinal study of blood pressure and dementia. Lancet. 1996;347:1141-1145.
18. Sparks DL, Scheff SW, Liu H, Landers TM, Coyne CM, Hunsaker JC. Increased incidence of neurofibrillary tangles (NFT) in non-demented individuals with hypertension. J Neurol Sci. 1995;131:162-169.
19. Tzourio C, Dufouil C, Ducimetiere P, Alperovitch A. Cognitive decline in individuals with high blood pressure. Neurology. 1999;53:1948-1954.
20. Launer LJ, Ross GW, Petrovitch H, Masaki K, Foley D, White LR, Havlik RJ. Midlife blood pressure and dementia: the Honolulu-Asia aging study. Neurobiol Aging. 2000;21:49-55.
21. Petrovitch H, White LR, Izmirilian G, Ross GW, Havlik RJ, Markesbery W, Nelson J, Davis DG, Hardman J, Foley DJ, Launer LJ. Midlife blood pressure and neuritic plaques, neurofibrillary tangles, and brain weight at death: the HAAS Honolulu-Asia aging study. Neurobiol Aging. 2000;21:57-62.
22. Kilander L, Nyman H, Boberg M, Hansson L, Lithell H. Hypertension is related to cognitive impairment: a 20-year follow-up of 999 men. Hypertension. 1998;31:780-786.
23. Forette F, Seux ML, Staessen JA, Thijs L, Babarskiene MR, Babeanu S, Bossini A, Fagard R, Gil-Extremera B, Laks T, Kobalava Z, Sarti C, Tuomilehto L, Vanhanen H, Webster J, Yodfat Y, Birkenhager WH, for the Systolic Hypertension in Europe Investigators. The prevention of dementia with antihypertensive treatment: new evidence for the Systolic Hypertension in Europe (Syst-Eur) study. Arch Intern Med. 2002;162:2046-2052.
24. Havlik RJ, Foley DJ, Sayer B, Masaki K, Whiter L, Launer LJ. Variability in midlife systolic blood pressure is related to late-life brain white matter lesions: the Honolulu-Asia Aging Study. Stroke. 2002;33:26-30.
25. Peila R, White LR, Petrovitch H, Masaki K, Ross GW, Havlik RJ, Launer LJ. Joint effect of the Apo E gene and midlife systolic blood pressure on late-life cognitive impairment: the Honolulu-Asia Aging Study. Stroke. 2001;32:2882-2889.
26. Skoog I, Gustafson D. Hypertension and related factors in the etiology of Alzheimer's disease. Ann N Y Acad Sci. 2002;977:29-36.
27. Kivipelto M, Laakso MP, Tuomilehto J, Nissinen A, Soininen H. Hypertension and hypercholesterolaemia as risk factors for Alzheimer's disease: potential for pharmacological intervention. CNS Drugs. 2002;16:435-444.
28. Qiu C, von Strauss E, Fastbom J, Winblad B, Fratiglioni L. Low blood pressure and risk of dementia in the Kungsholmen project: a 6-year follow-up study. Arch Neurol. 2003;60:223-228.
29. Kalmijn S, Launer LJ, Ott A, Witteman JCM, Hofman A, Breteler MMB. Dietary fat intake and the risk of incident dementia in the Rotterdam study. Ann Neurol. 1997;42:776-782.
30. Kivipelto M, Helkala EL, Hanninen T, Laakso MP, Hallihainen M, Alhainen K, Soininen H, Tuomilehto J, Nissinen A. Midlife vascular risk factors and late-life mild cognitive impairment: a population based study. Neurology. 2001;56:1683-1689.
31. Launer LJ, White LR, Petrovitch H, Ross GW, Curb JD. Cholesterol and neuropathological markers of AD: a population-based autopsy study. Neurology. 2001;57:1447-1452.
32. Kivipelto M, Helkala EL, Laakso MP, Hanninen T, Hallikaininen M, Alhainen K, Iivonen S, Mannermaa A, Tuomilehto J, Nissinen A, Soiniinen H. Apolipoprotein E ε4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer disease. Ann Intern Med. 2002;137:149-155.
33. Seshadri S, Beiser A, Selhub J, Jacques PF, Rosenberg IH, D'Agostino RB, Wilson PW, Wolf PA. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med. 2002;346:476-483.
34. Luchsinger JA, Tang MX, Stern Y, Shea S, Mayeux R. Diabetes mellitus and risk of Alzheimer's disease and dementia with stroke in a multiethnic cohort. Am J Epidemiol. 2001;154:635-641.
35. Knopman D, Boland LL, Mosley T, Howard G, Liao D, Szklo M, McGovern P, Folsom AR for the Atherosclerosis Risk in Communities (ARIC) Study Investigators. Cardiovascular risk factors and cognitive decline in middle-aged adults. Neurology. 2001;56:42-48.
36. Peila R, Rodriguez BL, Launer LJ. Type 2 diabetes, Apo E gene, and the risk of dementia and related pathologies: the Honolulu-Asia Aging Study. Diabetes. 2002;51:1256-1262.
37. Launer LJ. Demonstrating the case that AD is a vascular disease: epidemiological evidence. Ageing Res Rev. 2002;1:61-67.
38. Kuo YM, Emmerling MR, Bisgaier CL, Essenburg AD, Lampert HC, Drumm D, Roher AE. Elevated low-density lipoprotein in Alzheimer's disease correlates with brain Aβ 1-42 levels. Biochem Biophys Res Commun. 1998;252:711-715.
39. Lesser G, Kandiah K, Libow LS, Likourezos A, Breuer B, Marin D, Mohs R, Haroutunian V, Neufeld R. Elevated serum total and LDL cholesterol in very old patients with Alzheimer's disease. Dement Geriatr Cogn Disord. 2001;12:138-145.
40. Roher AE, Kuo YM, Kokjohn KM, Emmerling MR, Gracon S. Amyloid and lipids in the pathology of Alzheimer disease. Amyloid Int J Exp Clin Invest. 1999;6:136-145.
41. Mirra SS. The CERAD neuropathology protocol and consensus recommendations for the postmortem diagnosis of Alzheimer's disease: a commentary. Neurobiol Aging. 1997;18:S91-S94.
42. NIA-Reagan. Consensus recommendations for the postmortem diagnosis of Alzheimer's disease: the National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease. Neurobiol Aging. 1997;18:S1-S2.
43. Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol. 1991;82:239-259.
44. Hixson JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res. 1990;31:545-548.
45. Ilveskoski E, Perola M, Lehtimaki T, Laippala P, Savolainen V, Pajarinen J, Penttila A, Lalu KH, Mannikko A, Liesto KK, Koivula T, Karhunen PJ. Age-dependent association of apolipoprotein E genotype with coronary and aortic atherosclerosis in middle-aged men: an autopsy study. Circulation. 1999;100:608-613.
46. Vittinghoff E, Shlipak MG, Varosy PD, Furberg CD, Ireland CC, Khan SS, Blumenthal R, Barrett-Connor E, Hulley S. Risk factors and secondary prevention in women with heart disease: the Heart and Estrogen/progestin Replacement Study. Ann Intern Med. 2003;138:81-89.
47. Yaffe K, Barrett-Conner E, Lin F, Grady D. Serum lipoprotein levels, statin use, and cognitive function in older women. Arch Neurol. 2002;59:378-384.
48. Iadecola C, Gorelick PB. Converging pathogenic mechanisms in vascular and neurodegenerative dementia. Stroke. 2003;34:335-337.
49. Niwa K, Kazama K, Younkin L, Younkin SG, Carlson GA, Iadecola C. Cerebrovascular autoregulation is profoundly impaired in mice overexpressing amyloid precursor protein. Am J Physiol Heart Circ Physiol. 2002;283:H315-H323.
50. Iadecola C, Zhang F, Niwa K, Turner SK, Fischer E, Younkin S, Borchelt DR, Hsiao KK, Carlson GA. SOD1 rescues cerebral endothelial dysfunction in mice overexpressing amyloid precursor protein. Nature Neurosci. 1999;2:157-161.
51. Niwa K, Younkin L, Ebeling C, Turner SK, Westaway D, Younkin S, Hsiao Ashe K, Carlson GA. Iadecola C. Aβ1-40-related reduction in functional hyperemia in mouse neocortex during somatosensory activation. Proc Natl Acad Sci U S A. 2000;97:9735-9740.
52. Jagust WJ, Budinger TF, Reed BR. The diagnosis of dementia with single photon emission computed tomography. Arch Neurol. 1987;44:258-262.
53. Johnson KA, Mueller ST, Walshe TM, English RJ, Holman BL. Cerebral perfusion imaging in Alzheimer's disease: use of single photon emission computed tomography and iofetamine hydrochloride I 123. Arch Neurol. 1987;44:165-168.
54. Gonzalez RG, Fischman AJ, Guimaraes AR, Carr CA, Stern CE, Halpern EF, Growdon JH, Rosen BR. Functional MR in the evaluation of dementia: correlation of abnormal dynamic cerebral blood volume measurements with changes in cerebral metabolism on positron emission tomography with fluorodeoxyglucose F18. Am J Neuroradiol. 1995;16:1763-1770.
55. Harris GJ, Lewis RF, Satlin A, English CD, Scott TM, Yurgelun-Todd DA, Renshaw PF. Dynamic susceptibility contrast MR imaging of regional cerebral blood volume in Alzheimer disease: a promising alternative to nuclear medicine. Am J Neuroradiol. 1998;19:1727-1732.
56. Alsop DC, Detre JA, Grossman M. Assessment of cerebral blood flow in Alzheimer's disease by spin-labeled magnetic resonance imaging. Ann Neurol. 2000;47:93-100.
57. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines PL, Pericak-Vance MA. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 1993;261:921-923.
58. Roher AE, Kuo YM, Esh C, Knebel C, Weiss N, Kalback W, Luehrs DC, Beach TG, Weller RO, Kokjohn TA. Cortical and leptomeningeal cerebro-vascular amyloid and white matter pathology in Alzheimer's disease. Mol Med. 2003;9:112-122.
59. Sparks DL, Scheff SW, Hunsaker JC, Liu H, Landers T, Gross DR. Induction of Alzheimer like β-amyloid immunoreactivity in the brains of rabbits with dietary cholesterol. Exp Neurol. 1994;126:88-94.
60. Refolo LM, Malester B, LaFrancois J, Bryant-Thomas T, Wang R, Tint GS, Sambamurti K, Duff K, Pappolla MA. Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol Dis. 2000;7:321-331.
61. Bodovitz S, Klein WL. Cholesterol modulates α-secretase cleavage of amyloid precursor protein. J Biol Chem. 1996;271:4436-4440.
62. Racchi M, Baetta R, Salvietti N, Ianna P, Franceschini G, Paoletti R, Fumagalli R, Govoni S, Trabucchi M, Soma M. Secretory processing of amyloid precursor protein is inhibited by increase in cellular cholesterol content. Biochem J. 1997;322:893-898.
63. Simons M, Keller P, De Strooper B, Beyreuther K, Dotti CG, Simons K. Cholesterol depletion inhibits the generation of β-amyloid in hippocampal neurons. Proc Nat Acad Sci U S A. 1998;95:6460-6464.
64. Puglielli L, Konopka G, Pack-Chung E, Ingano LA, Berezovska O, Hyman BT, Chang TY, Tanzi RE, Kovacs DM. Acyl-coenzyme A: cholesterol acyltransferase modulates the generation of the β-peptide. Nature Cell Biol. 2001;3:905-912.
65. Refolo LM, Pappolla MA, LaFrancois J, Malester B, Schmidt SD, Thomas-Bryant T, Tint GS, Wamg R, Mercken M, Petanceska SS, Duff KE. A cholesterol-lowering drug reduces β-amyloid pathology in a transgenic mouse model of Alzheimer's disease. Neurobiol Dis. 2001;8:890-899.
66. Fassbender K, Simons M, Bergmann C, Stroick M, Lutjohann D, Keller P, Runz H, Kuhl S, Bertsch T, von Bergmann K, Hennerici M, Beyereuther K, Hartmann T. Simvastatin strongly reduces levels of Alzheimer's disease β-amyloid peptides Aβ 42 and Aβ 40 in vitro and in vivo. Proc Nat Acad Sci U S A. 2001;98:5856-5861.
67. Beach TG. The history of Alzheimer's disease: three debates. J Hist Med Allied Sci. 1987;42:327-349.
68. Sourander P, Sjogren H. The concept of Alzheimer's disease and its clinical implications. In: Wolstenholme GEW, O'Connor M, eds. Alzheimer's Disease and Related Conditions. London: J&A Churchill; 1970:11-36.
69. Kuczmarski RJ, Flegal KM, Campbell SM, Johnson CL. Increasing prevalence of overweight among US adults: the National Health and Nutrition Examination Surveys, 1960-1991. JAMA. 1994;272:205-211.
70. Flegal KM, Carrol MD, Ogden CL, Johnson CL. Prevalence and trends in obesity among US adults, 1999-2000. JAMA. 2002;288:1723-1727.
71. Allison DB, Fontaine KR, Manson JE, Stevens J, Vanltallie TB. Annual deaths attributable to obesity in the United States. JAMA. 1999;282:1530-1538.
72. Hahn RA, Teutsch SM, Rothenberg RB, Marks JS. Excess deaths from nine chronic diseases in the United States. JAMA. 1990;264:2654-2659.
73. McGinnis JM, Foege WH. Actual causes of death in the United States. JAMA. 1993;270:2207-2212.